Abstract
Background
Amyloid light chain (AL) amyloidosis is a rare disease with poor prognosis and limited therapeutic alternatives. Recently, one clinical case with cardiac involvement, as well as a compelling evidence of green tea polyphenol, epigallocatechin-3-gallate (EGCG), inducing the formation of benign aggregation products that do not polymerize into fibrils were published. This is a report of the cardiac effects of green tea consumption in these patients.
Methods
Patients with known cardiac involvement in AL amyloidosis were examined by routine cardiovascular examinations that took place every 3–6 months. Of 59 patients with cardiac involvement, 11 revealed a decrease of at least 2 mm of interventricular wall thickness, after initiation of regular green tea consumption (GT). A matched historic control group (n = 22) was selected. Comprehensive echocardiography was conducted at every control examination and analyzed offline by two independent examiners.
Results
GT patients showed an improvement in New York Heart Association (NYHA) class from a median of 3 (25th, 75th percentiles: 2, 3) to 2 (2, 3), P = 0.038. Septal thickness decreased from 18 (18, 20) to 16 (16, 17) mm, P = 0.021. Left ventricular mass index decreased from 175 (154, 180) to 133 (128, 154) g/m2, P = 0.007. Comparing both groups, an increase in left ventricular ejection fraction could be found in the GT group, 65 (51, 73) versus 53 (47, 59)%, P = 0.012. These changes could not be observed in the control group.
Conclusion
Consumption of green tea polyphenol EGCG in patients with cardiac involvement with AL amyloidosis causes a significant decrease in left ventricular wall thickness and mass, as well as an improvement in NYHA functional classification and left ventricular ejection fraction.
Similar content being viewed by others
References
Gertz MA, Comenzo R, Falk RH et al (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol 79:319–328
Gertz MA, Lacy MG, Dispenzieri A (2004) Therapy for immunoglobulin light chain amyloidosis: the new and the old. Blood Rev 18:17–37
Roig E, Almenar L, González-Vílchez F et al (2009) Outcomes of heart transplantation for cardiac amyloidosis: subanalysis of the Spanish registry for heart transplantation. Am J Transplant 9:1414–1419
Hunstein W (2007) Epigallocatechin-3-gallate in AL amyloidosis: a new therapeutic option? Blood 110:2216
Shammas MA, Neri P, Koley H et al (2006) Specific killing of multiple myeloma cells by (−)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications. Blood 108:2804–2810
Shanafelt TD, Lee YK, Call TG et al (2006) Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies. Leuk Res 30:707–712
Shanafelt TD, Call TG, Zent CS et al (2009) Phase I trial of daily oral polyphenon E in patients with asymptomatic Rai Stage 0 to II chronic lymphocytic leukemia. J Clin Oncol 27:3808–3814
Rezai-Zadeh K, Shytle D, Sun N et al (2005) Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci 25:8807–8814
Lorenz M, Hellige N, Rieder P et al (2008) Positive inotropic effects of epigallocatechin-3-gallate (EGCG) involve activation of Na+/H+ and Na+/Ca2 + exchangers. Eur J Heart Fail 10:439–445
Hao J, Kim CH, Ha TS, Ahn HY (2007) Epigallocatechin-3 gallate prevents cardiac hypertrophy induced by pressure overload in rats. J Vet Sci 8:121–129
Ehrnhoefer DE, Bieschke J, Boeddrich A et al (2008) EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol 15:558–566
Hauber I, Hohenberg H, Holstermann B et al (2009) The main green tea polyphenol epigallocatechin-3-gallate counteracts semen-mediated enhancement of HIV infection. Proc Natl Acad Sci USA 106:9033–9038
Mereles D, Wanker EE, Katus HA (2008) Therapy effects of green tea in a patient with systemic light-chain amyloidosis. Clin Res Cardiol 97:341–344
Lang RM, Bierig M, Devereux RB et al (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440–1463
Nagueh SF, Appleton CP, Gillebert TC et al (2009) Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 22:107–133
Yock PG, Popp RL (1984) Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 70:657–662
Ommen SR, Nishimura RA, Hurrel DG et al (2000) Assessment of right atrial pressure with 2-dimensional and Doppler-echocardiography: a simultaneous catheterization and echocardiography study. Mayo Clin Proc 75:24–29
Levy D, Anderson KM, Savage DD et al (1988) Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med 108:7–13
Siqueira-Filho AG, Cunha CL, Tajik AJ et al (1981) M-mode and two-dimensional echocardiographic features in cardiac amyloidosis. Circulation 63:188–196
Hongo M, Ikeda S (1986) Echocardiographic assessment of the evolution of amyloid heart disease: a study with familial amyloid polyneuropathy. Circulation 73:249–256
Klein AL, Hatle LK, Burstow DJ et al (1990) Comprehensive Doppler assessment of right ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 15:99–108
Klein AL, Hatle LK, Taliercio CP et al (1990) Serial Doppler echocardiographic follow-up of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 16:1135–1141
Bellavia D, Pellikka PA, Abraham TP et al (2008) Evidence of impaired left ventricular systolic function by Doppler myocardial imaging in patients with systemic amyloidosis and no evidence of cardiac involvement by standard two-dimensional and Doppler echocardiography. Am J Cardiol 101:1039–1045
Palladini G, Lavatelli F, Russo P et al (2006) Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 107:3854–3858
Jantunen E, Itälä M, Lehtinen T et al (2006) Early treatment-related mortality in adult autologous stem cell transplant recipients: a nation-wide survey of 1,482 transplanted patients. Eur J Haematol 76:245–250
Robertson IM, Li MX, Sykes BD (2009) The solution structure of human cardiac troponin C in complex with the green tea polyphenol; (−)-epigallocatechin-3-gallate. J Biol Chem 284:23012–23023
Liao R, Jain M, Teller P et al (2001) Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 104:1594–1597
Sheng R, Gu ZL, Xie ML et al (2009) EGCG inhibits proliferation of cardiac fibroblasts in rats with cardiac hypertrophy. Planta Med 75:113–120
Grünig E, Janssen B, Mereles D et al (2000) Abnormal pulmonary artery pressure response in asymptomatic carriers of primary pulmonary hypertension gene. Circulation 102:1145–1150
Henning SM, Niu Y, Liu Y et al (2005) Bioavailability and antioxidant effect of epigallocatechin gallate administered in purified form versus as green tea extract in healthy individuals. J Nutr Biochem 16:610–616
Chow HH, Hakim IA, Vining DR et al (2005) Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals. Clin Cancer Res 11:4627–4633
Author information
Authors and Affiliations
Corresponding author
Additional information
D. Mereles and S. J. Buss contributed equally to this work.
Rights and permissions
About this article
Cite this article
Mereles, D., Buss, S.J., Hardt, S.E. et al. Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis. Clin Res Cardiol 99, 483–490 (2010). https://doi.org/10.1007/s00392-010-0142-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00392-010-0142-x